Core Viewpoint - The incident involving the addition of a controlled substance, diazepam, to a traditional Chinese medicine (TCM) product highlights significant regulatory challenges in the pharmaceutical industry, particularly regarding the classification and oversight of TCM formulations [1][2][7] Regulatory Issues - The Hebei Puzhe Medical Service Co., Ltd. is under investigation for allegedly adding diazepam, a second-class controlled substance, to its TCM product, which raises questions about compliance with existing drug regulations [1][2] - The incident underscores the need for stricter enforcement of laws governing the production and sale of TCM, particularly regarding the classification of products as hospital preparations versus approved formulations [3][4] Legal Framework - According to the Pharmaceutical Administration Law and the TCM Law, medical institutions must obtain a preparation license and approval number for any formulations that include both TCM and chemical drugs, especially those containing controlled substances [2][3] - The lack of proper licensing and the potential for misleading information during the registration process can lead to severe penalties, including fines and criminal charges for responsible parties [3][4] Health Risks - The addition of diazepam to TCM products poses significant health risks, particularly for vulnerable populations such as the elderly, who may develop dependencies on these substances [4][5] - There are documented cases of similar violations across the country, indicating a broader issue of non-compliance and the potential for serious health consequences due to improper drug combinations [4][6] Industry Implications - The incident reflects a larger trend of inappropriate combinations of TCM and Western medicine, which can complicate treatment regimens and lead to adverse drug interactions [5][6] - The need for a comprehensive approach to address these regulatory and safety issues is critical for restoring public trust in the pharmaceutical industry and ensuring patient safety [7]

目前，该案件正在调查之中，将根据调查结果依法依规进行处置。 该局表示，将持续加大药品安全监管力度，切实保障群众用药安全。 据石家庄桥西发布微信公众号，5月19日，石家庄市桥西区市场监督管理局发布情况通报称，近日， 有媒体报道该区河北普泽医养服务有限公司石家庄中医医院生产销售的"中药液"涉嫌添加安眠药问 题。石家庄市桥西区市场监督管理局已就此问题对该医院进行立案调查。 ...

针对"消费者在石家庄一家医院购买治疗失眠的中药饮剂中含有安眠药"一事，5月19日，石家庄桥西区市场监 督管理局公开通报称，该局就此问题对涉事医院进行立案调查，目前，正在调查之中。 通报称，近日，有媒体报道桥西区河北普泽医养服务有限公司石家庄中医医院生产销售的"中药液"涉嫌添加安 眠药问题，桥西区市场监管局将根据调查结果依法依规进行处置。该局表示，将持续加大药品安全监管力度， 切实保障群众用药安全。 百万用户都在看 证监会重拳出手！3人，被罚没7.5亿元！ 美联储，突爆大消息！ 港股，重大调整！即将实施！ 利好来袭！芯片、特朗普，突传重磅！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 大斌表示，视频发出后有陌生人打来电话表示要联系协商，他未同意。 来源：澎湃新闻、大和报 责编：汪云鹏 校对：赵燕 此前，据大河报报道称，5月17日，网络博主大斌称，一位刘姓消费者通过互联网问诊，在石家庄普泽中医院 购买了治疗失眠的中药饮剂，服用后很快发困，经两家检测机构检测，均含有西药成分地西泮，剩余药剂已经 过公证并封存。 根据《精神药品管理条例》和《精神药品品种目录（2013年版）》，地 ...